The clinical outcomes of the AAVIATE study (NCT04514653) is discussed in this touchOPHTHALMOLOGY interview with Prof. Arshad Khanani (Sierra Eye Associates, Reno, NV, USA). RGX-314 is being developed as a potential one-time treatment for neovascular AMD as current anti-VEGF therapies require life-long intraocular injections to maintain efficacy. Due to the burden of treatment, patients often experience a decline in vision with reduced frequency of treatment over time.
The presentation entitled ‘Suprachoroidal Delivery of RGX-314 Gene Therapy for Neovascular AMD: The Phase II AAVIATE™ Study’ was presented at the The Association for Research in Vision and Ophthalmology, May 01-04, 2022.
Questions:
- What are the aims and methodology of the AAVIATE study?
- What have the initial findings taught us about the efficacy, safety and tolerability of RGX-314?
- Which patients are most likely to benefit from this treatment?
Disclosures: Arshad Khanani is a consultant for Regenxbio and discloses grant/research Support from Regenxbio.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Shanice Allen.
